Open AccessRisk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection
Author(s) -
Süleyman Sayar,
Kemal Kürbüz,
Resul Kahraman,
Oğuzhan Öztürk,
Zuhal Çalışkan,
Levent Doganay,
Kamil Özdil
Publication year - 2020
Publication title -
the turkish journal of gastroenterology/the turkish journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 28
eISSN - 2148-5607
pISSN - 1300-4948
DOI - 10.5152/tjg.2020.19295
Subject(s) - medicine , hbsag , hepatitis b virus , hepatitis b , immunology , gastroenterology , tumor necrosis factor alpha , virus , virology
Hepatitis B reactivation (HBVR) is an important risk of treatment with tumor necrosis factor inhibitors (anti-TNF). While antiviral prophylaxis is recommended before treatment in HBsAg-positive patients, there is no clear approach for the follow-up or prophylactic treatment of patients with past hepatitis B virus (HBV) infection. The aim of this study was to evaluate patients with past HBV infection treated with anti-TNF for HBVR and/or HBVR-associated biochemical breakthrough.